Showing 1 - 8 results of 8 for search 'Xiangyong Hao', query time: 0.03s Refine Results
  1. 1
    Impact of hepatic inflammation and fibrosis on the recurrence and long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after hepatectomy

    Impact of hepatic inflammation and fibrosis on the recurrence and long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after hepatectomy by Xiangyong Hao, Liangliang Xu, Xiang Lan, Bo Li, Hui Cai

    Published 2024-04-01
    Get full text
    Article
  2. 2
    Analysis of the characteristics and risk factors affecting the judgment results of medical damage liability disputes in 3172 second-instance and retrial cases in China

    Analysis of the characteristics and risk factors affecting the judgment results of medical damage liability disputes in 3172 second-instance and retrial cases in China by Yanfei Shen, Sheng Lei, Qi Wang, Hongjing Wang, Xiangyong Hao, Hui Cai

    Published 2023-06-01
    Get full text
    Article
  3. 3
    Analysis of the characteristics, efficiency, and influencing factors of third-party mediation mechanisms for resolving medical disputes in public hospitals in China

    Analysis of the characteristics, efficiency, and influencing factors of third-party mediation mechanisms for resolving medical disputes in public hospitals in China by Yanfei Shen, Gaiyun Li, Zhiguo Tang, Qi Wang, Zurong Zhang, Xiangyong Hao, Xuemei Han

    Published 2024-07-01
    Get full text
    Article
  4. 4
    CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth

    CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth by Liangliang Xu, Xinfu Feng, Xiangyong Hao, Peng Wang, Yanfang Zhang, Xiaobo Zheng, Lian Li, Shengsheng Ren, Ming Zhang, Mingqing Xu

    Published 2019-02-01
    Get full text
    Article
  5. 5
    Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

    Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy by Xin Su, Jian Li, Xiao Xu, Youbao Ye, Cailiu Wang, Guanglong Pang, Wenxiu Liu, Ang Liu, Changchun Zhao, Xiangyong Hao

    Published 2024-08-01
    Get full text
    Article
  6. 6
    Novel Prognostic Nomograms for Hepatocellular Carcinoma Patients with Microvascular Invasion: Experience from a Single Center

    Novel Prognostic Nomograms for Hepatocellular Carcinoma Patients with Microvascular Invasion: Experience from a Single Center by Liangliang Xu, Lian Li, Peng Wang, Ming Zhang, Yanfang Zhang, Xiangyong Hao, Lvnan Yan, Bo Li, Tianfu Wen, Mingqing Xu

    Published 2019-11-01
    Get full text
    Article
  7. 7
    Intravenous Pantoprazole as an Adjuvant Therapy following Successful Endoscopic Treatment for Peptic Ulcer Bleeding

    Intravenous Pantoprazole as an Adjuvant Therapy following Successful Endoscopic Treatment for Peptic Ulcer Bleeding by Jun Wang, Kehu Yang, Bin Ma, Jinhui Tian, Yali Liu, Zhenggang Bai, Lei Jiang, Shaoliang Sun, Jun Li, Ruifeng Liu, Xiangyong Hao, Xiaodong He

    Published 2009-01-01
    Get full text
    Article
  8. 8
    KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3

    KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3 by Tian Lan, Hui Li, Delin Zhang, Lin Xu, Hailing Liu, Xiangyong Hao, Xiaokai Yan, Haotian Liao, Xiangzheng Chen, Kunlin Xie, Jiaxin Li, Mingheng Liao, Jiwei Huang, Kefei Yuan, Yong Zeng, Hong Wu

    Published 2019-12-01
    Get full text
    Article

Search Tools: